We are delighted to announce that our CEO, Dr. Scott Dean, has been accepted into the prestigious MedTech Venture Builder programme at the London Institute for Healthcare Engineering (LIHE). The LIHE MedTech Venture Builder is the UK’s first dedicated venture builder for MedTech, offering an unmatched environment for early-stage innovators to develop and commercialise transformative healthcare technologies.
Scott will join a cohort of entrepreneurs working within a collaborative, multidisciplinary setting that provides access to part-time workspace for our team at LIHE, as well as expert guidance on regulatory strategy, market access, IP protection, clinical validation, and commercial planning.
This opportunity comes at a pivotal time for Graphene Trace. As we advance the development of our Sensore platform, begin regulatory preparations, and plan for clinical trials, Scott’s participation in the Venture Builder will provide strategic insight and support to help navigate the complex journey from prototype to market-ready product.
We’re incredibly proud of this milestone and the recognition it brings to our work. Scott’s involvement in the LIHE MedTech Venture Builder reinforces our commitment to building a clinically relevant, commercially viable solution that can make a meaningful difference in the prevention of pressure ulcers and the improvement of patient care.
Scott Dean
CEO
Share
